Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $1.48 $1.48 Wednesday, 30th Aug 2023 TCRR stock ended at $1.48. During the day the stock fluctuated 0% from a day low at $1.48 to a day high of $1.48.
90 days $1.48 $1.48
52 weeks $0.82 $2.87

Historical TCR2 Therapeutics Inc. prices

Date Open High Low Close Volume
Jul 26, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 25, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 24, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 21, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 20, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 19, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 18, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 17, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 14, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 13, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 12, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 11, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 10, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 07, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 06, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 05, 2023 $1.48 $1.48 $1.48 $1.48 0
Jul 03, 2023 $1.48 $1.48 $1.48 $1.48 0
Jun 30, 2023 $1.48 $1.48 $1.48 $1.48 0
Jun 29, 2023 $1.48 $1.48 $1.48 $1.48 0
Jun 28, 2023 $1.48 $1.48 $1.48 $1.48 0
Jun 27, 2023 $1.48 $1.48 $1.48 $1.48 0
Jun 26, 2023 $1.48 $1.48 $1.48 $1.48 0
Jun 23, 2023 $1.48 $1.48 $1.48 $1.48 0
Jun 22, 2023 $1.48 $1.48 $1.48 $1.48 0
Jun 21, 2023 $1.48 $1.48 $1.48 $1.48 0
Click to get the best stock tips daily for free!

About TCR2 Therapeutics Inc.

TCR2 Therapeutics. TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal... TCRR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT